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Abstract 
  In a country with a high prevalence (16%) of chronic serum HBsAg carriers like Romania there is a special 
interest in the diagnosis, epidemiology, clinics, pathology and treatment of HBV infection 
The idea of HBV genotyping arose from the need of understanding the complex interactions between virus and 
host. 
The purpose of this article is to present a study which aimed to identify the circulating HBV genotypes in 
Romania, correlate them with the clinical outcome and by HBV genotyping, to make a selection of patients for the most 
appropriate antiviral therapy. 
130 patients were selected, from different areas of the spectrum of HBV infection in which a quantitative 
determination of HBV-DNA was performed. 
HBV A genotype is associated with the inactive carrier status; a symptomatic HBV-HDV was identified in the 
double infection. The HBV D genotype has the most common HBV genotype (66%) and is associated with active viral 
infection and hepatocellular carcinoma. Long term HBV chronic infection revealed a mixture of A and D genotypes in 
most cases. 
For a proper selection of patient for the antiviral therapy, we should mandatorily genotype the HBV virus 
before the onset of treatment and all genotyping data must be correlated with liver biopsy assessments. 
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The worldwide health problem of chronic liver diseases caused by persistent infection with 
hepatitis B virus (HBV) has determined the rapid development of therapeutical strategies created in 
order to control the process of active viral replication and prevent subsequent clinical consequences 
such as cirrhosis and hepatocellular carcinoma. 
Chronic  HBV  hepatitis  centers  the  attention  of  modern  hepatology  as  there  are  an 
impressive number of 400 x 10
6 chronic carriers, HBV infection being the leading cause of liver 
cirrhosis and hepatocellular carcinoma [1]. It is estimated that approximately 1.1 million people die 
every year from HBV infection [2, 10]. 
The initial stages of hepatitis virus research in Romania can be easily defined and timelined, 
but later stages are harder to outline, since they overlap. Combined and complex methodologies 
involving more and more fields – virology, hepatology and immunology, have lead to the valid 
results that represent the basis of the huge edifice of current knowledge on viral hepatitis. 
In Romanian virology, study of viral hepatitis is an old tradition; for Stefan S. Nicolau and 
Nicolae Cajal researches on viral hepatitis represented a preferential subject, managing to formulate 
numerous  ethiopathogenic  concepts  with  high-priority  worldwide  diagnostics  and  introduce  the 
concept of pluriethiology of viral hepatitis [3]. 
Viral  hepatitis  has  been  and  continues  to  be  an  important  issue  in  Romanian  medical 
literature especially in respect to clinical aspects. 
Viral hepatitis represents a major public health problem in our country and constitutes for 
virologists the most dynamic objective of study and contemporary research. Journal of Medicine and Life  Vol. 1, No.2, April-June 2008 
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In a country with a high prevalence (16%) of chronic serum HBsAg carriers like Romania 
there is a special  interest in  the epidemiology, clinics, pathology and treatment of HBV infection 
[4]. 
HBV  carries  out  the  replication  of  its  DNA  genome  through  a  process  of  reverse 
transcription with shortcomings in the reading process, resulting in the HBV quasispecies. 
HBV A and D genotypes have different replication efficiencies in cell cultures and these 
characteristics are kept in vivo [9]. 
Often, the mutant variants, especially those in the “precore” and “core promoter” regions 
predominate together with the wild-type HBV in the same host. 
For the viral dominance, both intra-viral population and intra-host factors must be taken into 
account.  Mutants  can  develop  a  selective  advantage  within  the  infected  host  during  chronic 
infection. Negative HBeAg mutants have a biological advantage over the wild-type viral strains, so 
these strains are selected through the process of evolution 
 
The idea of HBV genotyping arose from the need of understanding the complex interactions 
between virus and host. 
In  the  80’s,  Vincent  Babeş  carried  out  the  first  study  on  HBV  serotyping  in  Romania, 
showing that the prevalent subtypes are: adw and ayw [3]. 
At that time, Babeş sustained that the clinical and prognostic value of HBV subtypes was 
controversial,  stressing  the  necessity  for  guided  research  based  on  a  unitary  and  standardized 
methodology. 
HBV is a noncytopathic virus, being the prototype virus of the Hepadnaviridae family. HBV 
is an enveloped virus with a circular DNA genome, partially double-stranded, of about 3.2 kbp. 
(Fig.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 HBV –  The  Hepadnaviridae family prototype Journal of Medicine and Life  Vol. 1, No.2, April-June 2008 
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Thus, after hepatocyte infection, genomic HBV DNA is transported into the nucleus, where 
it  is  transformed  into  a  covalently  closed  circular  DNA  molecule  (cccDNA)  [14].  cccDNA 
determines the transcription of viral mRNA for the generation of viral gene products. One of the 
viral mRNA molecules is larger than the genome and encodes for the capsid proteins [14]. 
After its translocation, the “core” protein will encase its own mRNA, known as pregenomic 
RNA to form the capsid [4]. 
The  pregenomic  RNA  is  subsequently  converted  to  the  partially  double-stranded  DNA 
genome by the DNA polymerase. The “core” particle will interact with the proteins of the viral 
envelope  that  had  been  inserted  into  the  membrane  of  the  endoplasmic  reticulum  (ER).  This 
interaction allows the “core”particle to enter the lumen of the ER and obtain its own envelope [4]. 
This viral particle released into the lumen of the ER is then secreted from the host cell. During the 
viral replication cycle three major viral antigens are produced, the “core” antigen, the “surface” 
antigen and the “e” antigen [14]. The HBV genome contains three open reading frames (ORF) that 
have overlapping regions and encode the “core” proteins, surface antigens, DNA polymerase and a 
transcriptional transactivator known as protein X [4]. 
The pre-S/S region has three starting points so that three forms of HBsAg are encoded: the 
proteins of the large envelope (L), of the medium envelope (M) and the small envelope (S).  
The  “precore-core”  region  has  two  starting  codons  that  produce  two  different  proteins: 
HBeAg and HBcAg, the structural component of the nucleocapsid. 
The  polymerase  gene  encodes  a  multifunctional  enzyme  with  multifunctional  enzymatic 
activities of reverse transcriptase, DNA polymerase and RNase. 
The X protein is a transactivator and can play a role in carcinogenesis. 
HBV replication allows reading errors of the ORF, thus resulting in variations of the initial 
infectant HBV strain. During the infection, variations of HBV sequences can be seen in almost all 
of the regions of the HBV genome. [15]. As a result of this phenomenon, HBV circulates in the 
form of quasispecies in infected patients, who carry different strains and genotypes [9]. 
 
Currently,  8  different  HBV  genotypes  have  been  identified  with  a  distinct  geographic 
distribution. Thus, genotype A (adw serotype) and D (ayw serotype) are frequently found in the 
United States and Europe [12]; genotype  B (adw) and C (adr) are prevalent in China and South-
East Asia [6]. In Romania, the prevalent serotypes were identified in the 80’s by Vincent Babeş and 
were adw and ayw [3]. 
Recent data suggests that there are differences in the clinical evolution and in the sustained 
virological response to antiviral therapy which is closely correlated with the HBV genotype. 
Thus, the A HBV genotype was associated with a favorable disease evolution and long-term 
survival  [11].  The  B  HBV  genotype  was  associated  with  the  development  of  hepatocellular 
carcinoma. C HBV genotype was associated with severe disease progression [6, 11]. 
Keeping in mind these aspects, we were interested in genotyping HBV, continuing the work 
of our virology professors and gaining a better understanding of the virus-host relationship, the 
sustained response to antiviral therapy, the outcome of chronic infection and the progression to 
hepatocellular carcinoma. 
 
Goals of the study 
 
-  to identify the circulating HBV genotypes in Romania 
-  to correlate HBV genotypes with clinical outcome 
-  by  HBV  genotyping,  to  make  a  selection  of  patients  for  the  most  appropriate  antiviral 
therapy 
 
Patients 
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A number of 130 patients were selected, divided in the following groups: 35 serum HBsAg 
asymptomatic carriers, with serum HBeAb positive, nonsignificant viral replication, normal ALT 
and minimal liver tissue changes; 15 patients with chronic hepatitis, serum HBsAg and HBeAb, low 
to  moderate  viral  replication,  high  serum  level  of  ALT,  HDV  coinfection  and  aggressive  liver 
histology features (Fig. 3); 68 patients with serum HBsAg and HbeAb positive, high serum levels of 
ALT, and high  viral replication having aggressive liver biopsy characteristics; 12 patients with 
serum HBsAg and HBeAb positive, associated with hepatocellular carcinoma, high serum levels of 
ALT, high viral replication, high serum levels of -fetoprotein (AFP) and hepatocellular carcinoma 
changes in liver. 
 
Materials and Methods 
 
All patients were tested for the presence of HBsAg, HBcAb, HBsAb, HBeAg and HBeAb in 
the serum. The quantitative determination of HBV-DNA was performed with HBV 2.0 Monitor 
(Roche Molecular Diagnostics). 
HBV genotyping was performed using the INNO-LiPA DR amplification kit and INNO-
LiPA genotyping kit (Innogenetics). 
The  amplification  reaction  preceding  the  genotyping  process  is  a  PCR  reaction,  using 
“outer”  and  “nested”  biotinylated  oligonucleotide  primers,  consequently  generating  biotinylated 
amplified  DNA  of  the  HBV-pol  gene  of  strains  B  to  C  and  obtaining  10  L  of  HBV,  DR 
amplification product in the open reading frame of the polymerase gene at codon 180 – 204 – 207. 
INNO-LiPA  Test  principle:    the  test  is  based  on  the  reverse  hybridization  principle: 
amplified  biotinylated  DNA  material  is  chemically  denatured,  and  the  separated  strands  are 
hybridized with specific oligonucleotide probes immobilized as parallel lines on membrane – based 
strips. This is followed by a stringent wash step to remove any mismatched amplified material. 
After the stringent wash, streptavidin conjugated with alkaline phosphatase is added and bound to 
any  biotinylated  hybrid  previously  formed.  Incubation  with  a  substrate  solution  containing  a 
chromogen results in a purple/brown precipitate. 
The reaction is stopped by a wash step, and reactivity pattern of the probes is recorded. 
 
Results 
 
The HBV – DNA amplicons are shown in Fig. 2 
 
RESULTS – Amplification products of HBV-DNA 
 
 
Fig. 2 HBV-DNA   amplicons Journal of Medicine and Life  Vol. 1, No.2, April-June 2008 
  169 
The HBV genotypes identified for the 130 selected patients were: 
 
-  A  HBV Genotype – 6 patients representing 5% 
-  D  HBV Genotype – 15 patients representing 12% 
-  A HBV and D HBV Genotype – 97 patients representing 75% 
-  (A+D+F; D+F) HBV Genotype combinations  – 12 patients representing 
9% 
See Fig.3 and Fig.4 
                 
       D Genotype           D+F Genotype      D+A 
Genotype      A Genotype 
 
Fig.3 HBV genotyping results 
 
 
HBV genotypes in Romania 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 HBV genotypes in 130 chronic HBV patients  
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These data correlate with the clinical, biochemical and histopathological status of patients. 
The conclusions of the HBV genotyping study are: HBV A genotype is associated with the 
inactive carrier status; a symptomatic  HBV-HDV was identified in the double infection. The HBV 
D  genotype  has  the  most  common  HBV  genotype  (66%)  and  is  associated  with  active  viral 
infection and hepatocellular carcinoma. (Fig. 5, Fig. 6, Fig. 7 and Fig. 8) 
Long term HBV chronic infection revealed a mixture of A and D genotypes in most cases. 
 
                                                      Chronic HBV infection 
 
 
Fig. 5 Section of liver showing normal architecture with regularly spaced portal tract (PT) and hepatic ve nues 
(HV). Haematoxylin and eosin stain; magnification approximately x35. (16) 
 
Chronic HBV-HDV infection 
 
 
Fig. 6 Low HBV - DNA replication associated with ‘ground-glass’ hepatocytes. Cells with a large amount of 
HBsAg in the cytoplasm appear pale and uniformly pink with haematoxylin and trs/sin stain. (16)  
 
Chronic HBV infection 
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Fig. 7 High viral replication associated with the presence of HBcAg (core antigen) in nuclei and cytoplasm 
(brown staining) (16) 
 
 
 
 
Fig. 8 HBV-associated HBsAg hepatocellular carcinoma. Hepatocellular carcinoma cells distinguished 
by an increased nucleocytoplasmic ratio and a darker staining pattern. Numerous cells have a 'ground glas s' 
appearance, resulting from the expression of HBsAg. Magnification approximately x150. (16)  
 
 
Discussion 
 
Currently, mutations are known to occur during chronic HBV infection at the nucleotide 
sequence level of HBV genome and have important clinical and virological case consequences. 
Thus, a mutation in the S gene that includes the substitution of glycine with arginine at 
codon 145 (G145R) was frequently found in new-born from HBsAg-positive mothers, for whom the 
HBV infection evolved in spite of vaccination at birth. In addition, this mutation was detected in 
patients with liver transplant that developed recurrent HBV infection, despite the therapy with HIBg 
immunoglobulin. The “core promoter” and “precore” variants produce HBV virions that do not 
secrete HBeAg [5]. 
The most frequent “precore promoter” mutation has a dual alteration A1762T and G1764A that 
diminishes “precore” mRNA and thus the secretion of HBeAg [8, 15]. 
These variants are found particularly in patients that do not have serum HBeAg, belonging 
to B, C and D genotypes. The G1896A premature stop codon mutation should also be mentioned 
[13]. 
In severe acute and chronic hepatitis cases “precore” HBV variants have been described [5]. 
Mutations in the polymerase gene were identified in patients undergoing antiviral therapy 
who  develop  antiviral  resistance.  The  best  characterized  mutants  in  the  polymerase  gene  were 
identified during lamivudine therapy. 
M552V,  M552I,  L528M,  (YMDD)  mutations  occur  in  the  catalytic  domain  of  the 
polymerase providing resistance to lamivudine and related nucleosidic analogs [7]. 
Preliminary sequencing data of circulating HBV strains in Romania were determined by our 
working  group  together  with  our  colleagues  from  London,  UK  (T.J.  Harrison,  R.  Ling,  I. 
Constantinescu – unpublished data, 2000). 
The patients with chronic HBV infection that were selected for sequencing had different 
clinical outcomes of the disease, either aggressive or biochemically and histologically mild. Our 
target  was  to  find  a  possible  correlation  between  eventual  HBV  “core  promoter”  mutants  and 
clinical and paraclinical aspects. 
Preliminary data showed in the high replicative and aggressive chronic HBV infection cases 
mutations of the stop codon type: 28 Tryptophan -> stop codon; 131 Arginine -> Lysine (aac -> 
aaa); 145 Glycine -> Arginine (gga -> aga). 
This study is in progress and the final results will offer new aspects of “core promoter” 
mutations and the clinical and histopathological evolution of HBV-induced chronic infection. Journal of Medicine and Life  Vol. 1, No.2, April-June 2008 
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The genotyping data presented above showed a closely correlation between HBV genotypes 
and clinical and histopatological outcome. 
Genotype D HBV is associated with long term survival and the chronic carrier status of 
HBV infection.  
Genotype D expresses a high replicative chronic HBV infection with serious histological 
changes. 
Genotype D - seems to be in associated with the development of HCC. 
Long  term  chronic  HBV  infection  is  characterized  by  a  mixture  of  (A+D+F)  HBV 
genotypes. 
For a proper selection of patient for the antiviral therapy, we should mandatorily genotype 
the HBV virus before the onset of treatment. 
All genotyping data correlated with liver biopsy assessments. ( Fig. 5, Fig. 6, Fig. 7 and Fig. 
8) 
For A HBV genotyping the most suitable attitude should by follow-up. 
For  genotype D the most adequate treatment should be nucleoside analogs (lamivudine, 
adefovir, entecavir). 
For  the  mixed  A+D  HBV  genotype,  combination  therapy  -  nucleoside  analogs  and 
interferon should be the best therapeutical attitude. 
In the general population wild-type HBV still predominates over other mutant forms. 
Furthermore,  the  stop  codon  mutant  form  in  the  “precore”  region  is  associated  with 
fulminant hepatitis and is much more frequently encountered in the D genotype of HBV [5]. In 
Romania, the prevalent genotype of HBV is D and it is important to genotype and find mutations in 
the  viral  genome  in  order  to  choose  the  most adequate  antiviral  therapy  and  provide  the  most 
accurate predicted outcome. 
In such cases, the therapy of choice is lamivudine, which acts on the dominant “precore” 
mutant variant. 
It is known that IFN has a potential antiviral activity only on the wild type strain. Therefore, 
the therapeutic decision must be taken on a case-by-case basis, only after a molecular virology 
diagnostic, in order to obtain a sustained virological answer, in fact, a therapeutic success. 
 
Conclusions  
 
HBV  molecular  virology  studies  provide  a  unique  understanding  of  the  virus-host 
relationship with an important impact on the evolution of the hepatitis infection and its possible 
outcome, but especially on the selection of patients for antiviral therapy. 
In conclusion, without a molecular virology diagnosis we cannot successfully understand 
and treat a chronic HBV infection. 
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